Department of Psychiatry, Division on Substance Abuse, Columbia University Medical Center/NYSPI, 1051 Riverside Drive, Unit 66, New York, NY 10032, United States.
Schizophr Res. 2013 Dec;151(1-3):197-202. doi: 10.1016/j.schres.2013.10.018. Epub 2013 Nov 5.
Studies to date showing an association between cannabis use and schizophrenia-spectrum disorders are of relatively small sample sizes with limitations in generalizability. The present study addresses this gap by examining the relationship between cannabis use and psychotic-like symptoms in a large representative community sample.
Data were derived from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, Wave 2), a large, nationally representative sample of 34,653 adults from the United States population. We evaluated the association between lifetime cannabis use, psychosis, and schizotypal personality features.
The prevalence of psychosis and schizotypal personality disorder increased significantly with greater cannabis use in a dose-dependent manner. The associations between cannabis use and psychosis were 1.27 (95% CI 1.03-1.57) for lifetime cannabis use, 1.79 (95% CI 1.35-2.38) for lifetime cannabis abuse, and 3.69 (95% CI 2.49-5.47) for lifetime cannabis dependence. There was a similar dose-response relationship between the extent of cannabis use and schizotypal personality disorder (OR=2.02 for lifetime cannabis use, 95% CI 1.69-2.42; OR=2.83 for lifetime cannabis abuse, 95% CI 2.33-2.43; OR=7.32 for lifetime cannabis dependence, 95% CI 5.51-9.72). Likelihood of individual schizotypal features increased significantly with increased extent of cannabis use in a dose-dependent manner.
This is the first population-based study to examine the association between lifetime cannabis use, psychosis, and schizotypal personality traits. These results add to evidence that cannabis use may be a risk factor for psychosis liability.
迄今为止,研究表明大麻使用与精神分裂症谱系障碍之间存在关联,但这些研究的样本量相对较小,存在推广的局限性。本研究通过在一个大型代表性社区样本中检查大麻使用与类精神病症状之间的关系,解决了这一差距。
数据来自于美国全国酒精和相关条件流行病学调查(NESARC,第 2 波),这是一项大型的、具有全国代表性的 34653 名成年人的样本。我们评估了终生大麻使用、精神病和精神分裂样人格特征之间的关联。
在剂量依赖性的方式下,精神病和精神分裂样人格障碍的患病率随着大麻使用量的增加而显著增加。大麻使用与精神病之间的关联为:终生大麻使用为 1.27(95%CI 1.03-1.57),终生大麻滥用为 1.79(95%CI 1.35-2.38),终生大麻依赖为 3.69(95%CI 2.49-5.47)。大麻使用程度与精神分裂样人格障碍之间也存在类似的剂量反应关系(终生大麻使用的 OR=2.02,95%CI 1.69-2.42;终生大麻滥用的 OR=2.83,95%CI 2.33-2.43;终生大麻依赖的 OR=7.32,95%CI 5.51-9.72)。个体精神分裂样特征的可能性随着大麻使用程度的增加而显著增加,呈剂量依赖性。
这是第一项研究终生大麻使用、精神病和精神分裂样人格特质之间关联的基于人群的研究。这些结果增加了大麻使用可能是精神病易感性的风险因素的证据。